Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Ther. 2013 Apr 19;12(5):685–695. doi: 10.1158/1535-7163.MCT-12-1066

Figure 1.

Figure 1

Polyclonal antibodies to different epitopes of SFRP2 inhibit SVR angiosarcoma tube formation.

ECMatrix was thawed, diluted and solidified in a 96 well plate. SVR angiosarcoma cells were seeded onto the matrix at a concentration of 1×104 cells / well in 150 μl of DMEM with 10% FBS. Sera from mice immunized against peptides sequences from SFRP2 (see Materials and Methods for peptide sequences, designated AbA, AbB, AbC, AbD, AbE, or control sera), were added to the wells at 1:100 dilution and incubated for 8 hours. Results were quantified by counting the number of branch points. SVR cells in control sera formed tubes, whereas antibodies to peptide A, B, C, and D all inhibited tube formation. AbB and AbC had the greatest inhibition (p<0.001, n=4 for all groups). B) Representative photographs of angiosarcoma tube formation.